Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2012

EMD Millipore Institutes Personalized Medicine Services

  • EMD Millipore's discovery and development solutions business is now offering genomic biomarker services. Company officials say the purpose is to aid drug companies in targeting patient sub-groups for improved clinical outcomes, understanding drug safety and efficacy, and characterizing tumors. The new qPCR and pyrosequencing-based services add to the company's existing protein- and cell-based solutions, which include ELISA, multiplex, and flow cytometry platforms, as well as its extensive experience in assay development, validation, and sample testings, according to Christina Shasserre, vp of discovery and development.

    Researchers at EMD Millipore recently profiled transcription in gefitinib-treated non-small cell lung cancer cells by qRT-PCR. The genotypic and mRNA expression data were then cross-validated with protein expression using flow cytometry and multiplex assays, solidifying the connection between the genotype and phenotype of interest. These types of connections provide confidence to preclinical and clinical decision-makers regarding drug safety and efficacy, continued Shasserre.

    "The drug development process is undergoing a paradigm shift from a 'one size fits all' model to 'Precision Medicine,'" says Shasserre. "Genomic information remains a critical part of this transformation. At EMD Millipore, we have the platforms, the scientific expertise and the experience running assays to help our customers develop their genomic biomarkers and enable them to successfully deliver on this new paradigm."

    PricewaterhouseCoopers, which estimated the U.S. market for personalized medicine at $232 billion three years ago, projects that this number will grow to as much as $452 billion by 2015.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »